Long-term costs of introducing hpv-dna post-treatment surveillance to national cervical cancer screening in ireland
Agapova, Maria Duignan, Andrea Smith, Alan O’Neill, Ciaran Basu, Anirban
Agapova, Maria
Duignan, Andrea
Smith, Alan
O’Neill, Ciaran
Basu, Anirban
Identifiers
http://hdl.handle.net/10379/10127
https://doi.org/10.13025/28603
https://doi.org/10.13025/28603
Repository DOI
Publication Date
2015-09-17
Type
Article
Downloads
Citation
Agapova, Maria; Duignan, Andrea; Smith, Alan; O’Neill, Ciaran; Basu, Anirban (2015). Long-term costs of introducing hpv-dna post-treatment surveillance to national cervical cancer screening in ireland. Expert Review of Pharmacoeconomics & Outcomes Research 15 (6), 999-1005
Abstract
Introduction: Co-testing (cytology plus human papillomavirus DNA testing) as part of cervical cancer surveillance in Ireland increases one-time testing costs. Of interest to policy makers was the long-term impact of these costs accompanied by decreases in intensity of recalls for women with no detected abnormalities. Methods: A cost analysis of cytology-only and co-testing strategy was implemented using decision analytic modeling, aggregating testing utilization and costs for each of the two strategies over 12 years. Results: Aggregated incremental costs of the co-testing strategy were positive for the first 3 years but became negative thereafter, generating a cost savings of roughly Euro20 million in favor of the cytology-only strategy over a 12-year period. Results were robust over a range of sensitivity analyses with respect to discount and attrition rates. Discussion: This analysis provided valuable information to policy makers contributing to the introduction of co-testing for post-treatment surveillance (PTS) in Ireland.
Funder
Publisher
Informa UK Limited
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland